US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HELUS PHARMA INC

10.72

+0.21002.00%

Pre-market: 10.830.1100+1.03%07:31 EDT

Volume:1.12M

Turnover:11.78M

Market Cap:783.21M

PE:-2.65

High:10.79

Open:10.50

Low:10.19

Close:10.51

52wk High:15.15

52wk Low:3.76

Shares:73.06M

Float Shares:58.48M

Volume Ratio:0.88

T/O Rate:1.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0491

EPS(LYR):-3.8923

ROE:-86.94%

ROA:-44.38%

PB:3.24

PE(LYR):-2.75

Loading ...

Overview Company News Filings

Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003

Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin

Simply Wall St.

Helus Pharma price target lowered to $15 from $30 at Alliance Global

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD)

Cybin Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate

Benzinga Earnings

Calendar of U.S. Earnings Expected in the Week Ahead

Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds

Simply Wall St.

Cybin Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Helus Pharma Closes $50 Million Underwritten Offering

MT Newswires Live

Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder

MT Newswires Live

Helus Pharma Prices $50 Million Underwritten Offering

MT Newswires Live

Helus Pharma prices 10.31M common shares at $4.85 in public offering

We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully

Simply Wall St.

H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)

How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative

Simply Wall St.

Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health

H.C. Wainwright Sticks to Its Buy Rating for Helus Pharma (HELP)

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","market":"US","secType":"STK","nameCN":"HELUS PHARMA INC","latestPrice":10.72,"timestamp":1791489600000,"preClose":10.51,"halted":0,"volume":1117053,"hourTrading":{"tag":"盘前","latestPrice":10.83,"preClose":10.72,"latestTime":"07:31 EDT","volume":1270,"amount":13643.85003,"timestamp":1791545462039,"change":0.11,"changeRate":0.010261,"amplitude":0.010261},"delay":0,"changeRate":0.019980970504281718,"floatShares":58481100,"shares":73060200,"eps":-4.049081,"marketStatus":"Pre-Mkt","change":0.21,"latestTime":"10-09 07:40:23 EDT","open":10.5,"high":10.79,"low":10.19,"amount":11783805.501635998,"amplitude":0.057088,"askPrice":10.8,"askSize":4,"bidPrice":10.14,"bidSize":12,"shortable":3,"etf":0,"ttmEps":-4.049081,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":10.72,"preHourTrading":{"tag":"盘前","latestPrice":10.83,"preClose":10.72,"latestTime":"07:31 EDT","volume":1270,"amount":13643.85003,"timestamp":1791545462039,"change":0.11,"changeRate":0.010261,"amplitude":0.010261},"postHourTrading":{"tag":"盘后","latestPrice":10.8381,"preClose":10.72,"latestTime":"19:57 EDT","volume":15563,"amount":166789.5416,"timestamp":1791503825545,"change":0.1181,"changeRate":0.011017,"amplitude":0.017547},"volumeRatio":0.8764648116713758,"impliedVol":1.7307,"impliedVolPercentile":0.6927},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","floatShares":58481100,"roa":"-44.38%","roe":"-86.94%","lyrEps":-3.892309,"volumeRatio":0.8764648116713758,"shares":73060200,"dividePrice":0,"high":10.79,"amplitude":0.057088,"preClose":10.51,"low":10.19,"week52Low":3.76,"pbRate":"3.24","week52High":15.15,"institutionHeld":0,"latestPrice":10.72,"committee":0.5,"eps":-4.049081,"divideRate":0,"volume":1117053,"delay":0,"ttmEps":-4.049081,"open":10.5,"prevYearClose":8.18,"prevWeekClose":11.7,"prevMonthClose":12.29,"prevQuarterClose":12.29,"fiveDayClose":11.91,"twentyDayClose":12.84,"sixtyDayClose":6.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HELP","fiscalQuarterEnding":"2026/06","expectedEps":-0.8,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.91},{"market":"US","date":"2026-06-29","symbol":"HELP","fiscalQuarterEnding":"2026/03","expectedEps":-1.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1782705600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2026-02-13","symbol":"HELP","fiscalQuarterEnding":"2025/12","expectedEps":-0.53,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1789790400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HELP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HELP","date":"2026-10-08","current":-2.647514,"percent":0.206349,"low":-5.982942,"twenty":-4.513542,"median":-2.882306,"eighty":-1.972725,"high":-1.57152,"avg":-3.249778,"sd":1.313034,"marketCap":767862407},"quantilePoints":[{"date":"2026-01-09","current":-4.237274,"twenty":-4.344211,"median":-4.257397,"eighty":-4.216576,"marketCap":367789729},{"date":"2026-01-16","current":-4.513243,"twenty":-4.471847,"median":-4.329263,"eighty":-4.240723,"marketCap":391743470},{"date":"2026-01-23","current":-4.432752,"twenty":-4.4477,"median":-4.415504,"eighty":-4.256821,"marketCap":384756963},{"date":"2026-01-30","current":-3.892312,"twenty":-4.44425,"median":-4.332138,"eighty":-4.197028,"marketCap":337847553},{"date":"2026-02-06","current":-3.369121,"twenty":-4.439651,"median":-4.243023,"eighty":-3.91531,"marketCap":292435253},{"date":"2026-02-13","current":-3.403617,"twenty":-4.425853,"median":-4.199903,"eighty":-3.703734,"marketCap":295429471},{"date":"2026-02-20","current":-2.801935,"twenty":-4.400556,"median":-4.133785,"eighty":-3.477209,"marketCap":345246985},{"date":"2026-02-27","current":-3.151162,"twenty":-4.339612,"median":-3.892312,"eighty":-3.128422,"marketCap":388277769},{"date":"2026-03-06","current":-2.290278,"twenty":-4.333863,"median":-3.768701,"eighty":-3.012284,"marketCap":282201883},{"date":"2026-03-13","current":-2.083178,"twenty":-4.318914,"median":-3.656589,"eighty":-2.772698,"marketCap":256683628},{"date":"2026-03-20","current":-1.953233,"twenty":-4.27062,"median":-3.450978,"eighty":-2.359311,"marketCap":240672173},{"date":"2026-03-27","current":-1.888261,"twenty":-4.241873,"median":-3.369121,"eighty":-2.142465,"marketCap":232666446},{"date":"2026-04-02","current":-2.026327,"twenty":-4.237274,"median":-3.151162,"eighty":-1.973537,"marketCap":249678617},{"date":"2026-04-10","current":-2.127847,"twenty":-4.214276,"median":-3.041521,"eighty":-2.026327,"marketCap":262187565},{"date":"2026-04-17","current":-2.233427,"twenty":-4.185529,"median":-2.883151,"eighty":-2.079117,"marketCap":275196872},{"date":"2026-04-24","current":-2.334946,"twenty":-4.168281,"median":-2.755237,"eighty":-2.079117,"marketCap":287705821},{"date":"2026-05-01","current":-2.156272,"twenty":-4.099289,"median":-2.473013,"eighty":-2.079117,"marketCap":265690071},{"date":"2026-05-08","current":-2.168454,"twenty":-3.949806,"median":-2.332915,"eighty":-2.083178,"marketCap":267191145},{"date":"2026-05-15","current":-2.054753,"twenty":-3.892312,"median":-2.278095,"eighty":-2.070996,"marketCap":253181122},{"date":"2026-05-22","current":-1.867957,"twenty":-3.817571,"median":-2.245609,"eighty":-2.001963,"marketCap":230164657},{"date":"2026-05-29","current":-1.823288,"twenty":-3.808372,"median":-2.233427,"eighty":-1.952421,"marketCap":224660719},{"date":"2026-06-05","current":-1.798924,"twenty":-3.746279,"median":-2.217184,"eighty":-1.904504,"marketCap":221658571},{"date":"2026-06-12","current":-1.644614,"twenty":-3.694535,"median":-2.188759,"eighty":-1.887449,"marketCap":202644969},{"date":"2026-06-18","current":-1.859835,"twenty":-3.668088,"median":-2.162363,"eighty":-1.864708,"marketCap":229163941},{"date":"2026-06-26","current":-2.444587,"twenty":-3.642791,"median":-2.156272,"eighty":-1.87283,"marketCap":301215485},{"date":"2026-07-02","current":-2.630171,"twenty":-3.565692,"median":-2.168454,"eighty":-1.879327,"marketCap":389260009},{"date":"2026-07-10","current":-2.776757,"twenty":-3.45355,"median":-2.19891,"eighty":-1.885824,"marketCap":410954437},{"date":"2026-07-17","current":-2.948472,"twenty":-3.424315,"median":-2.233427,"eighty":-1.891509,"marketCap":436367909},{"date":"2026-07-24","current":-3.237455,"twenty":-3.399137,"median":-2.237487,"eighty":-1.896382,"marketCap":479136922},{"date":"2026-07-31","current":-3.40917,"twenty":-3.401377,"median":-2.263883,"eighty":-1.897194,"marketCap":504550394},{"date":"2026-08-07","current":-4.648869,"twenty":-3.432324,"median":-2.290278,"eighty":-1.901255,"marketCap":688023265},{"date":"2026-08-14","current":-4.795455,"twenty":-3.679587,"median":-2.339007,"eighty":-1.904504,"marketCap":709717693},{"date":"2026-08-21","current":-4.514739,"twenty":-3.872812,"median":-2.466832,"eighty":-1.909377,"marketCap":772941452},{"date":"2026-08-28","current":-5.650082,"twenty":-4.154483,"median":-2.567348,"eighty":-1.928869,"marketCap":967316677},{"date":"2026-09-04","current":-5.022769,"twenty":-4.209892,"median":-2.630171,"eighty":-1.93293,"marketCap":859918224},{"date":"2026-09-11","current":-5.479385,"twenty":-4.237274,"median":-2.732902,"eighty":-1.949173,"marketCap":938092608},{"date":"2026-09-18","current":-5.982942,"twenty":-4.329263,"median":-2.766884,"eighty":-1.953233,"marketCap":1024303611},{"date":"2026-09-25","current":-5.372699,"twenty":-4.410143,"median":-2.797698,"eighty":-1.969476,"marketCap":919827565},{"date":"2026-10-02","current":-5.082514,"twenty":-4.44425,"median":-2.841674,"eighty":-1.969476,"marketCap":870146648},{"date":"2026-10-08","current":-4.485073,"twenty":-4.513542,"median":-2.882306,"eighty":-1.972725,"marketCap":767862407}],"updateTime":1791546023185},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653060422","title":"Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003","url":"https://stock-news.laohu8.com/highlight/detail?id=2653060422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653060422?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:05","pubTimestamp":1784646331,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder. APP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218051","title":"Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218051","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218051?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:17","pubTimestamp":1784542665,"startTime":"0","endTime":"0","summary":"We'd be surprised if Cybin Inc. ( NASDAQ:HELP ) shareholders haven't noticed that the Chief Financial Officer, Greg...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651109798","title":"Helus Pharma price target lowered to $15 from $30 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2651109798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651109798?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:41","pubTimestamp":1784036468,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on Helus Pharma (HELP) to $15 from $30 and keeps a Buy rating on the shares, based on a sum-of-the-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-price-target-lowered-to-15-from-30-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-price-target-lowered-to-15-from-30-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650237379","title":"Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650237379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650237379?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:20","pubTimestamp":1783592423,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Helus Pharma (HELP) and Mettler-Toledo (MTD) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-and-mettler-toledo-mtd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-and-mettler-toledo-mtd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4137","IE00B5TLWC47.USD","BK4121","IE00BFXG0V08.USD","XLV","BK4588","LABU","LU1093756168.USD","XBI","LU0029874061.USD","LU2413666426.HKD","BK4567","LU2413666699.HKD","IE00BYQQ9H92.USD","LU1721428933.USD","BK4007","BK4533","LU0128526141.USD","BK4581","HELP","LU0347712357.USD","LU2211817866.USD","BK4585","LU1093756325.SGD","MTD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302057","title":"Cybin Inc Reports Results for the Quarter Ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302057","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302057?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:03","pubTimestamp":1782766994,"startTime":"0","endTime":"0","summary":"Cybin Inc reports results for the quarter ended March 31 - Earnings SummaryCybin IncHELP.NLBreported a quarterly adjusted loss of C$1.17 per share for the quarter ended March 31, higher than the same ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL8N4311WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647743963","title":"Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647743963","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647743963?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:46","pubTimestamp":1782737209,"startTime":"0","endTime":"0","summary":"Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.11) by 23.42 percent. This is a 16.67 percent increase over losses of $(1.02) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60154129/helus-pharma-q4-eps-0-85-beats-1-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378925","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647378925?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:00","pubTimestamp":1782727200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. Constellation Brands Inc. Class A                1Q      3.20       AMC. NIKE Inc. Class B                                4Q       .12   4:15 PM. FactSet Research Syss Inc.                       3Q      4.45   6:00 AM. MSC Indus Direct Co. Inc. Class A                3Q      1.27   6:30 AM. Lindsay Corp.                                    3Q      1.14   6:45 AM Dow Jones NewswiresJune 29, 2026 06:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LNN","LU2210149790.SGD","LU1585245621.USD","LU2552382058.USD","NKE","LU0889566641.SGD","LU0786609619.USD","LU1267930573.SGD","AVAV","LU1267930227.SGD","LU2065169927.USD","BK4152","LU2065732104.USD","PRGS","LU0792757196.USD","BK4547","LU1303367103.USD","BK4226","BK4104","FDS","UNF","GBX","LU2098885051.SGD","IE00BYQQ9H92.USD","AVXX","GIS","LU0310800379.SGD","LU2065170008.USD","LU0029864427.USD","AMC","BK4106","BK4532","BK4112","LU2095319765.USD","LU0052756011.USD","BK4007","BK4504","LU2552382215.SGD","BK4149","STZ","LU1267930813.SGD","MSM","LU2552382132.HKD","FC","HELP","BK4123","BK4581","LU0823411888.USD","CNXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647343036","title":"Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2647343036","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647343036?lang=en_us&edition=fundamental","pubTime":"2026-06-29 03:08","pubTimestamp":1782673723,"startTime":"0","endTime":"0","summary":"Cybin (HELP) is drawing fresh attention after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%, a key marker in its broader PARADIGM program.\nSee our latest analysis for Cybin.\nThe recent APPROACH trial update comes after a sharp short term rebound in Cybin's 1 week and 1 month share price returns of 38.76% and 42.42% respectively. This is set against a year to date share price return that is still down 21.74% and a 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646436701","title":"Cybin Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2646436701","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646436701?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:02","pubTimestamp":1782504142,"startTime":"0","endTime":"0","summary":"Cybin Incexpected to post a loss of93cents a share - Earnings PreviewCybin IncHELP.NLBis expected to  show no change in quarterly revenue when it reports  results on June 29 (estimated) for the period","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL8N42Y1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646355768","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2646355768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646355768?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:00","pubTimestamp":1782468000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. Constellation Brands Inc. Class A                1Q      3.23       AMC. NIKE Inc. Class B                                4Q       .13   4:15 PM. FactSet Research Syss Inc.                       3Q      4.45   6:00 AM. MSC Indus Direct Co. Inc. Class A                3Q      1.27   6:30 AM. Lindsay Corp.                                    3Q      1.14   6:45 AM Dow Jones NewswiresJune 26, 2026 06:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889566641.SGD","BK4112","LU1585245621.USD","BK4104","FDS","APOG","STZ","IE00BFXG0V08.USD","BK4226","LU1303367103.USD","BK4588","LNN","NKE","HELP","PRGS","LU2095319765.USD","AMC","LU0128525929.USD","LU1267930227.SGD","LU2552382215.SGD","BK4108","FC","LU2210150020.SGD","UNF","LU1267930573.SGD","LU0310800379.SGD","LU0786609619.USD","BK4533","CNXC","GBX","BK4123","LU0128525689.USD","LU2065171402.SGD","LU2552382058.USD","BK4082","XAIR","LU0823411888.USD","MSM","BK4581","AVXX","BK4007","AVAV","GIS","BK4146","LU1430594728.SGD","BK4212","LU2065732104.USD","LU0029864427.USD","BK4532","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646070805","title":"Helus Pharma Closes $50 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2646070805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646070805?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:50","pubTimestamp":1782395442,"startTime":"0","endTime":"0","summary":"Helus Pharma  closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.The company said it paid underwriters a $3 million cash commission.Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.Shares of the company were up 4% in early Thursday trading.Price: 5.38, Change: +0.29, Percent Change: +5.70","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645089714","title":"Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645089714","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645089714?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:29","pubTimestamp":1782300560,"startTime":"0","endTime":"0","summary":"Helus Pharma  said Wednesday that enrollment in its phase 3 clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86%.The company said it remains on track to report topline data from the study in Q4.Shares of the company were up 7.8% in Wednesday's premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894086","title":"Helus Pharma Prices $50 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645894086?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:37","pubTimestamp":1782297473,"startTime":"0","endTime":"0","summary":"Helus Pharma  has priced an underwritten public offering of 10.3 million common shares at $4.85 apiece for aggregate gross proceeds of $50 million, the company said Wednesday.The company said it will use the proceeds to advance its HLP003, HLP004 and HLP005 programs, including HLP003 for major depressive disorder, with phase 3 data expected in the fourth quarter.The offering is expected to close Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645012894","title":"Helus Pharma prices 10.31M common shares at $4.85 in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645012894","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645012894?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:35","pubTimestamp":1782297320,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the company at an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-prices-10-31m-common-shares-at-4-85-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-prices-10-31m-common-shares-at-4-85-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748908","title":"We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748908","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748908?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:42","pubTimestamp":1781692941,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/we-think-cybin-nasdaqhelp-needs-to-drive-business-growth-car","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/we-think-cybin-nasdaqhelp-needs-to-drive-business-growth-car","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQJ","GPIQ","FTEC","HELP","IYW","NVIW.SI","BK4007",".IXIC","TQQY","QID","ONEQ","QQQY","QLD","TECS","QDTE","SQQQ","QQQM","NQmain","PSQ","QYLG","JEPQ","QQQA","QQQ","QQQE","TQQQ","NDX","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631584986","title":"H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631584986","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631584986?lang=en_us&edition=fundamental","pubTime":"2026-04-29 00:35","pubTimestamp":1777394137,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $95.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629006290","title":"How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2629006290","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629006290?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:14","pubTimestamp":1776924878,"startTime":"0","endTime":"0","summary":"Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding neuroscience veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs.\nThis combination of a board-driven leadership change and a high-profile medical affairs hire could influence how investors assess Helus’ execution capabilities within Cybin’s broader clinical platform.\nWe’ll now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779874","title":"Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779874","media":"Dow Jones","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629779874?lang=en_us&edition=fundamental","pubTime":"2026-04-21 09:54","pubTimestamp":1776736485,"startTime":"0","endTime":"0","summary":"An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Trump Supports Using Drugs Like LSD for Mental Health","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","DFTX","HELP","BK4539","BK4007","BK4139","CMPS","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629202777","title":"H.C. Wainwright Sticks to Its Buy Rating for Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629202777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629202777?lang=en_us&edition=fundamental","pubTime":"2026-04-21 01:37","pubTimestamp":1776706649,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $95.00. Trucchio ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724864","title":"Helus ‘welcomes’ Executive Order for accelerating psychedelic research","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724864","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628724864?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:47","pubTimestamp":1776696420,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-welcomes-executive-order-for-accelerating-psychedelic-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-welcomes-executive-order-for-accelerating-psychedelic-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}